Cite
MLA Citation
Anna Maria Fink et al.. “Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study.” Lancet, vol. 4, no. 10, 2017, pp. e475–e486. http://access.bl.uk/ark:/81055/vdc_100050154384.0x000023